Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
—
0.7506BGN
95.21 MBGN
1.87 BBGN
40.03 M
About SOPHARMA AD BGN1
Sector
CEO
Ognian Ivanov Donev
Headquarters
Sofia
Website
Founded
1933
ISIN
BG11SOSOBT18
FIGI
BBG00JHW2KL9
Sopharma AD engages in the provision of pharmaceutical business. Its operations include production and marketing of medical products, medicinal substances as well as dosage forms. It also involved in research, engineering, and implementation activities in the field of phytochemistry, chemistry, and pharmacy. The firm offers dermatological products, gastroenterological, as well as psychoneurological, antiallergic and others. The company was founded in 1933 and is headquartered in Sofia, Bulgaria.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0KWF is 4.2600 BGN — it has decreased by 0.23% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange SOPHARMA AD BGN1 stocks are traded under the ticker 0KWF.
SOPHARMA AD BGN1 is going to release the next earnings report on May 30, 2024. Keep track of upcoming events with our Earnings Calendar.
Yes, you can track SOPHARMA AD BGN1 financials in yearly and quarterly reports right on TradingView.
0KWF net income for the last quarter is 17.47 M BGN, while the quarter before that showed 14.28 M BGN of net income which accounts for 22.32% change. Track more SOPHARMA AD BGN1 financial stats to get the full picture.
Today SOPHARMA AD BGN1 has the market capitalization of 997.04 M, it has increased by 1.43% over the last week.
Like other stocks, 0KWF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SOPHARMA AD BGN1 stock right from TradingView charts — choose your broker and connect to your account.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SOPHARMA AD BGN1 EBITDA is 142.57 M BGN, and current EBITDA margin is 8.05%. See more stats in SOPHARMA AD BGN1 financial statements.